Related coverage linked through entity extraction aliases.
Apr 20, 2026
New data from the American Cancer Society shows the U.S. cancer death rate has dropped 34% since 1991, preventing nearly five million deaths. More than 18 million Americans are living after a cancer diagnosis, with that number expected to surpass 22 million by 2030.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 20, 2026
A pan-cancer study identified 56 local cellular programs and 13 spatial niches across 12 cancer types. Multiple niches were linked to prognosis, immunotherapy response, and macrophage spatial distribution.
Apr 17, 2026
Needle-free allergy therapy is forecast to expand through 2035 as self-administered options gain share. House dust mite allergy treatment is projected to grow from $3.18 billion in 2025 to $8.75 billion by 2033.
Apr 09, 2026
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.
Apr 07, 2026
A retrospective study of 692 matched HNSCC trials found that sponsor-driven decisions and poor recruitment were the leading causes of early termination. The analysis also identified enrollment, funding source, trial phase, and inclusion of procedures or surgery as factors associated with failure.
Apr 06, 2026
Illuminate 3.0 brought global and Indian oncology experts to Mumbai for a three-day townhall on precision oncology, immunotherapy, cellular therapies and cancer vaccines. Discussions covered CAR-T cell therapy, multi-cancer early detection and access to novel drugs in India.
Apr 05, 2026
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
Apr 03, 2026
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
Apr 03, 2026
The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
Apr 02, 2026
FDA has cleared a robotic nipple-sparing mastectomy platform after clinical trials showed excellent results with preserved breast sensation. Researchers are advancing immunotherapy combinations for breast cancer and novel strategies to overcome drug resistance in EGFR-mutated lung cancer, including protein degraders and dual-binding inhibitors.
Apr 02, 2026
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
Apr 01, 2026
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Apr 01, 2026
Research reveals therapy-induced senescent cancer cells and the integrated stress response pathway play dual roles in cancer immunotherapy resistance. The ATF4-LCN2 axis suppresses anti-tumor immunity by promoting immunosuppressive macrophages, while senescent cells can both enhance and inhibit immune responses. These findings highlight new targets for improving immunotherapy efficacy.
Mar 31, 2026
Clinical trials take 10-15 years and cost $1-2 billion from discovery to approval, progressing through four phases from safety testing to real-world monitoring. These studies face challenges including high costs, regulatory oversight, and participant recruitment while new technologies are transforming trial design. Illinois faces a shortage of Phase I clinical trial facilities despite local companies conducting over 50 such trials annually.
Mar 28, 2026
The phase III TOP study shows osimertinib plus chemotherapy more than doubles progression-free survival to 34 months versus 15.6 months with osimertinib alone in EGFR/TP53 mutant NSCLC. The combination achieved an 82.9% response rate and represents a new strategy for this high-risk subgroup. Research continues into resistance mechanisms, including cancer-associated fibroblasts' role in promoting osimertinib resistance.
Mar 28, 2026
A Phase 3 trial shows administering immunochemotherapy before 3:00 PM improves survival outcomes in advanced NSCLC. Early treatment resulted in 11.3 months progression-free survival versus 5.7 months for late treatment, and 28.0 months overall survival versus 16.8 months. The findings suggest treatment timing is a modifiable factor that can enhance efficacy without additional cost.
Mar 26, 2026
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
Mar 25, 2026
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
Mar 24, 2026
Immunotherapy is increasingly used in earlier cancer stages before or after surgery across seven tumor areas. Research shows neoadjuvant and adjuvant immunotherapy can reduce recurrence risk and improve immune recognition of tumor cells. However, challenges remain including side effects, costs, and determining which patients benefit most from earlier treatment.
